

David R Andes

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6189406/david-r-andes-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

214 papers	19,867 citations	64 h-index	139 g-index
241 ext. papers	23,452 ext. citations	7.1 avg, IF	6.86 L-index

#	Paper	IF	Citations
214	Preventing Biofilms on Indwelling Catheters by Surface-Bound Enzymes.. <i>ACS Applied Bio Materials</i> , 2021 , 4, 8248-8258	4.1	0
213	Contributions of Extracellular Vesicles to Fungal Biofilm Pathogenesis.. <i>Current Topics in Microbiology and Immunology</i> , 2021 , 432, 67-79	3.3	0
212	A small molecule produced by <i>Lactobacillus</i> species blocks <i>Candida albicans</i> filamentation by inhibiting a DYRK1-family kinase. <i>Nature Communications</i> , 2021 , 12, 6151	17.4	9
211	Coordination of fungal biofilm development by extracellular vesicle cargo. <i>Nature Communications</i> , 2021 , 12, 6235	17.4	6
210	Folate Functionalized Lipid Nanoparticles for Targeted Therapy of Methicillin-Resistant. <i>Pharmaceutics</i> , 2021 , 13,	6.4	3
209	Turbinmicin inhibits <i>Candida</i> biofilm growth by disrupting fungal vesicle-mediated trafficking. <i>Journal of Clinical Investigation</i> , 2021 , 131,	15.9	10
208	Model-Informed Drug Development for Anti-Infectives: State of the Art and Future. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 109, 867-891	6.1	10
207	The Role of New Posaconazole Formulations in the Treatment of <i>Candida albicans</i> Infections: Data from an Pharmacokinetic-Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , 65,	5.9	4
206	Evolution of the complex transcription network controlling biofilm formation in species. <i>ELife</i> , 2021 , 10,	8.9	7
205	Managing uncertainty in antifungal dosing: antibiograms, therapeutic drug monitoring and drug-drug interactions. <i>Current Opinion in Infectious Diseases</i> , 2021 , 34, 288-296	5.4	1
204	Implementation of telehealth antimicrobial stewardship through partnership of an academic medical center and a community hospital. <i>American Journal of Health-System Pharmacy</i> , 2021 , 78, 2256-2264	2.2	0
203	Novel approaches for the treatment of methicillin-resistant <i>Staphylococcus aureus</i> : Using nanoparticles to overcome multidrug resistance. <i>Drug Discovery Today</i> , 2021 , 26, 31-43	8.8	16
202	The protein kinase Ire1 impacts pathogenicity of <i>Candida albicans</i> by regulating homeostatic adaptation to endoplasmic reticulum stress. <i>Cellular Microbiology</i> , 2021 , 23, e13307	3.9	9
201	A Dual-Responsive Antibiotic-Loaded Nanoparticle Specifically Binds Pathogens and Overcomes Antimicrobial-Resistant Infections. <i>Advanced Materials</i> , 2021 , 33, e2006772	24	31
200	Echinocandins 2021 , 438-448		
199	Chemical Exchanges between Multilateral Symbionts. <i>Organic Letters</i> , 2021 , 23, 1648-1652	6.2	4
198	Formation and characterization of biofilms formed by salt-tolerant yeast strains in seawater-based growth medium. <i>Applied Microbiology and Biotechnology</i> , 2021 , 105, 2411-2426	5.7	2

197	Global guideline for the diagnosis and management of the endemic mycoses: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology. <i>Lancet Infectious Diseases</i> , 2021 , 21, e364-e374	25.5	16
196	Specialized Metabolites Reveal Evolutionary History and Geographic Dispersion of a Multilateral Symbiosis. <i>ACS Central Science</i> , 2021 , 7, 292-299	16.8	7
195	An oxindole efflux inhibitor potentiates azoles and impairs virulence in the fungal pathogen <i>Candida auris</i> . <i>Nature Communications</i> , 2020 , 11, 6429	17.4	15
194	Toward Harmonization of Voriconazole CLSI and EUCAST Breakpoints for <i>Candida albicans</i> Using a Validated Pharmacokinetic/Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9	2
193	Pyridine-2,6-Dithiocarboxylic Acid and Its Metal Complexes: New Inhibitors of New Delhi Metallo- β -Lactamase-1. <i>Marine Drugs</i> , 2020 , 18,	6	1
192	Old In Vitro Antimicrobial Breakpoints Are Misleading Stewardship Efforts, Delaying Adoption of Innovative Therapies, and Harming Patients. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa084	1	2
191	Contributions of the Biofilm Matrix to Pathogenesis. <i>Journal of Fungi (Basel, Switzerland)</i> , 2020 , 6,	5.6	27
190	Pharmacodynamic Evaluation of Omadacycline against <i>Staphylococcus aureus</i> in the Neutropenic Mouse Pneumonia Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9	6
189	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. <i>Clinical Infectious Diseases</i> , 2020 , 71, 1367-1376	11.6	607
188	A marine microbiome antifungal targets urgent-threat drug-resistant fungi. <i>Science</i> , 2020 , 370, 974-978	33.3	39
187	Biomineral armor in leaf-cutter ants. <i>Nature Communications</i> , 2020 , 11, 5792	17.4	11
186	Core Recommendations for Antifungal Stewardship: A Statement of the Mycoses Study Group Education and Research Consortium. <i>Journal of Infectious Diseases</i> , 2020 , 222, S175-S198	7	39
185	Achievement of clinical isavuconazole blood concentrations in transplant recipients with isavuconazonium sulphate capsules administered via enteral feeding tube. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 3023-3028	5.1	7
184	Pharmacodynamic Evaluation of MRX-8, a Novel Polymyxin, in the Neutropenic Mouse Thigh and Lung Infection Models against Gram-Negative Pathogens. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9	7
183	Pharmacodynamic Target Determination for Delafloxacin against <i>Klebsiella pneumoniae</i> and <i>Pseudomonas aeruginosa</i> in the Neutropenic Murine Pneumonia Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	3
182	Determination of Pharmacodynamic Target Exposures for Rezafungin against <i>Candida tropicalis</i> and <i>Candida dubliniensis</i> in the Neutropenic Mouse Disseminated Candidiasis Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	8
181	Exploiting the vulnerable active site of a copper-only superoxide dismutase to disrupt fungal pathogenesis. <i>Journal of Biological Chemistry</i> , 2019 , 294, 2700-2713	5.4	10
180	APX001 Pharmacokinetic/Pharmacodynamic Target Determination against in an Model of Invasive Pulmonary Aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	26

179	The antimicrobial potential of Streptomyces from insect microbiomes. <i>Nature Communications</i> , 2019 , 10, 516	17.4	110
178	Bacterial Infections in the Stem Cell Transplant Recipient and Hematologic Malignancy Patient. <i>Infectious Disease Clinics of North America</i> , 2019 , 33, 399-445	6.5	9
177	Small-Molecule Morphogenesis Modulators Enhance the Ability of 14-Helical Peptides To Prevent Candida albicans Biofilm Formation. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	2
176	Pharmacokinetic/Pharmacodynamic Evaluation of Solithromycin against Streptococcus pneumoniae Using Data from a Neutropenic Murine Lung Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	3
175	Pharmacodynamics of Omadacycline against Staphylococcus aureus in the Neutropenic Murine Thigh Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	15
174	A targeted fungal prophylaxis protocol with static dosed fluconazole significantly reduces invasive fungal infection after liver transplantation. <i>Transplant Infectious Disease</i> , 2019 , 21, e13156	2.7	7
173	The Candida albicans biofilm gene circuit modulated at the chromatin level by a recent molecular histone innovation. <i>PLoS Biology</i> , 2019 , 17, e3000422	9.7	7
172	Characterization of an Uncinocarpus reesii-expressed recombinant tube precipitin antigen of Coccidioides posadasii for serodiagnosis. <i>PLoS ONE</i> , 2019 , 14, e0221228	3.7	1
171	MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 3056-3062	5.1	29
170	Impact of Triazole Therapeutic Drug Monitoring Availability and Timing. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	10
169	Pyonitrins A-D: Chimeric Natural Products Produced by. <i>Journal of the American Chemical Society</i> , 2019 , 141, 17098-17101	16.4	11
168	In vivo pharmacodynamics of lefamulin, the first systemic pleuromutilin for human use, in a neutropenic murine thigh infection model. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, iii5-iii10	5.1	11
167	WCK 5222 (Cefepime/Zidebactam) Pharmacodynamic Target Analysis against Metallo- β -lactamase producing in the Neutropenic Mouse Pneumonia Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 ,	5.9	13
166	Variability and exposure-response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 761-767	5.1	31
165	Pharmacokinetic/Pharmacodynamic Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model against Staphylococcus aureus and Streptococcus pneumoniae. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	9
164	Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	15
163	How Clean Is the Linen at My Hospital? The Mucorales on Unclean Linen Discovery Study of Large United States Transplant and Cancer Centers. <i>Clinical Infectious Diseases</i> , 2019 , 68, 850-853	11.6	19
162	Bacterial-derived exopolysaccharides enhance antifungal drug tolerance in a cross-kingdom oral biofilm. <i>ISME Journal</i> , 2018 , 12, 1427-1442	11.9	73

161	Pharmacokinetics-pharmacodynamics, computer decision support technologies, and antimicrobial stewardship: the compass and rudder. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018 , 91, 371-382	2.9	5
160	Conservation and Divergence in the Species Biofilm Matrix Mannan-Glucan Complex Structure, Function, and Genetic Control. <i>MBio</i> , 2018 , 9,	7.8	34
159	Pharmacokinetics and Pharmacodynamics of APX001 against <i>Candida</i> spp. in a Neutropenic Disseminated Candidiasis Mouse Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	45
158	Identification of the Pharmacokinetics and Pharmacodynamic Driver of Iclaprim. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	6
157	We can do better: a fresh look at echinocandin dosing. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, i44-i50	5.1	25
156	Methodologies for and evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms. <i>Microbial Cell</i> , 2018 , 5, 300-326	3.9	57
155	Pharmacodynamic Characterization of a Novel Odilorhabdin Antibiotic, NOSO-502, against <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> in a Murine Thigh Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	6
154	Isavuconazole Concentration in Real-World Practice: Consistency with Results from Clinical Trials. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	65
153	Topical delivery of ebselen encapsulated in biopolymeric nanocapsules: drug repurposing enhanced antifungal activity. <i>Nanomedicine</i> , 2018 , 13, 1139-1155	5.6	25
152	Pharmacodynamics of a Long-Acting Echinocandin, CD101, in a Neutropenic Invasive-Candidiasis Murine Model Using an Extended-Interval Dosing Design. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	36
151	1389. Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model Against <i>S. aureus</i> (SA) and <i>S. pneumoniae</i> (SPN). <i>Open Forum Infectious Diseases</i> , 2018 , 5, S426-S426	1	1
150	<i>Candida</i> -streptococcal interactions in biofilm-associated oral diseases. <i>PLoS Pathogens</i> , 2018 , 14, e1007348	3.48	61
149	<i>Candida albicans</i> biofilm-induced vesicles confer drug resistance through matrix biogenesis. <i>PLoS Biology</i> , 2018 , 16, e2006872	9.7	107
148	Pharmacodynamic Evaluation of Rezafungin (CD101) against <i>Candida auris</i> in the Neutropenic Mouse Invasive Candidiasis Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	38
147	In Vivo <i>Candida</i> Device Biofilm Models 2017 , 93-113		
146	Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against <i>Streptococcus pneumoniae</i> in the Murine Pneumonia Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	32
145	Antifungal Efficacy of an Intravenous Formulation Containing Monomeric Amphotericin B, 5-Fluorocytosine, and Saline for Sodium Supplementation. <i>Pharmaceutical Research</i> , 2017 , 34, 1115-1124	4.5	7
144	<i>Candida</i> Biofilm Tolerance: Comparison of Planktonic and Biofilm Resistance Mechanisms 2017 , 77-92		3

143	Pharmacokinetics and Pharmacodynamics of ZTI-01 (Fosfomycin for Injection) in the Neutropenic Murine Thigh Infection Model against <i>Escherichia coli</i> , <i>Klebsiella pneumoniae</i> , and <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	51
142	Pharmacodynamic Target Assessment of Eravacycline against <i>Escherichia coli</i> in a Murine Thigh Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	25
141	The Role of Biofilm Matrix in Mediating Antifungal Resistance 2017 , 369-384		2
140	Comparative Pharmacodynamics of Telavancin and Vancomycin in the Neutropenic Murine Thigh and Lung Infection Models against <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	19
139	Pharmacodynamic Optimization for the Treatment of Invasive <i>Candida auris</i> Infection. <i>Open Forum Infectious Diseases</i> , 2017 , 4, S73-S73	1	78
138	In vivo infection models in the pre-clinical pharmacokinetic/pharmacodynamic evaluation of antimicrobial agents. <i>Current Opinion in Pharmacology</i> , 2017 , 36, 94-99	5.1	23
137	<i>Candida albicans</i> FRE8 encodes a member of the NADPH oxidase family that produces a burst of ROS during fungal morphogenesis. <i>PLoS Pathogens</i> , 2017 , 13, e1006763	7.6	34
136	Traditional PK-PD Indices for Efficacy [Can We Do Better?]. <i>Open Forum Infectious Diseases</i> , 2017 , 4, S298-S298		1
135	Pharmacological Basis of CD101 Efficacy: Exposure Shape Matters. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	18
134	Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	52
133	Distinct roles of the 7-transmembrane receptor protein Rta3 in regulating the asymmetric distribution of phosphatidylcholine across the plasma membrane and biofilm formation in <i>Candida albicans</i> . <i>Cellular Microbiology</i> , 2017 , 19, e12767	3.9	9
132	The Role of In Vitro Susceptibility Testing in the Management of <i>Candida</i> and <i>Aspergillus</i> . <i>Journal of Infectious Diseases</i> , 2017 , 216, S452-S457	7	13
131	Breaking New Ground: An Evaluation of Susceptibility Breakpoints for Echinocandins against <i>Candida</i> Species. <i>Open Forum Infectious Diseases</i> , 2017 , 4, S298-S298	1	
130	Pharmacodynamic Optimization for Treatment of Invasive <i>Candida auris</i> Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	53
129	Dual action antifungal small molecule modulates multidrug efflux and TOR signaling. <i>Nature Chemical Biology</i> , 2016 , 12, 867-75	11.7	50
128	Animal models in the pharmacokinetic/pharmacodynamic evaluation of antimicrobial agents. <i>Bioorganic and Medicinal Chemistry</i> , 2016 , 24, 6390-6400	3.4	57
127	The epidemiology and outcomes of invasive <i>Candida</i> infections among organ transplant recipients in the United States: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). <i>Transplant Infectious Disease</i> , 2016 , 18, 921-931	2.7	101
126	Global Identification of Biofilm-Specific Proteolysis in <i>Candida albicans</i> . <i>MBio</i> , 2016 , 7,	7.8	45

125	Large-scale production and isolation of Candida biofilm extracellular matrix. <i>Nature Protocols</i> , 2016 , 11, 2320-2327	18.8	15
124	In Vivo Pharmacodynamic Target Assessment of Delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a Murine Lung Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 4764-9	5.9	34
123	The Extracellular Matrix of Fungal Biofilms. <i>Advances in Experimental Medicine and Biology</i> , 2016 , 931, 21-35	3.6	32
122	Intraluminal Release of an Antifungal Peptide Enhances the Antifungal and Anti-Biofilm Activities of Multilayer-Coated Catheters in a Rat Model of Venous Catheter Infection. <i>ACS Biomaterials Science and Engineering</i> , 2016 , 2, 112-121	5.5	22
121	Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2016 , 62, 409-17	11.6	1105
120	Targeting Fibronectin To Disrupt In Vivo Candida albicans Biofilms. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 3152-5	5.9	12
119	Antifungal Agents: Spectrum of Activity, Pharmacology, and Clinical Indications. <i>Infectious Disease Clinics of North America</i> , 2016 , 30, 51-83	6.5	182
118	Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2016 , 62, e1-50	11.6	1655
117	Fungal Super Glue: The Biofilm Matrix and Its Composition, Assembly, and Functions. <i>PLoS Pathogens</i> , 2016 , 12, e1005828	7.6	60
116	Transcriptional rewiring over evolutionary timescales changes quantitative and qualitative properties of gene expression. <i>ELife</i> , 2016 , 5,	8.9	32
115	Bypass of Candida albicans Filamentation/Biofilm Regulators through Diminished Expression of Protein Kinase Cak1. <i>PLoS Genetics</i> , 2016 , 12, e1006487	6	29
114	Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses for Delafloxacin to Provide Dose Selection Support for the Treatment of Patients With Community-Acquired Bacterial Pneumonia (CABP). <i>Open Forum Infectious Diseases</i> , 2016 , 3,	1	1
113	Animal Models to Evaluate Anti-infective Pharmacodynamics. <i>Methods in Pharmacology and Toxicology</i> , 2016 , 59-87	1.1	2
112	Antifungal Pharmacokinetics and Pharmacodynamics. <i>Methods in Pharmacology and Toxicology</i> , 2016 , 369-383	1.1	
111	Pleiotropic effects of the vacuolar ABC transporter MLT1 of Candida albicans on cell function and virulence. <i>Biochemical Journal</i> , 2016 , 473, 1537-52	3.8	21
110	Drug-Drug Interaction Associated with Mold-Active Triazoles among Hospitalized Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 3398-406	5.9	39
109	Commensal Protection of Staphylococcus aureus against Antimicrobials by Candida albicans Biofilm Matrix. <i>MBio</i> , 2016 , 7,	7.8	141
108	In vivo pharmacokinetics and pharmacodynamics of the lantibiotic NAI-107 in a neutropenic murine thigh infection model. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 1258-64	5.9	28

107	Phaeohyphomycosis in transplant recipients: Results from the Transplant Associated Infection Surveillance Network (TRANSNET). <i>Medical Mycology</i> , 2015 , 53, 440-6	3.9	65
106	Community participation in biofilm matrix assembly and function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, 4092-7	11.5	103
105	The synthesis of indolo[2,3-b]quinoline derivatives with a guanidine group: highly selective cytotoxic agents. <i>European Journal of Medicinal Chemistry</i> , 2015 , 105, 208-19	6.8	27
104	In Vivo Pharmacodynamic Evaluation of an FtsZ Inhibitor, TXA-709, and Its Active Metabolite, TXA-707, in a Murine Neutropenic Thigh Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 6568-74	5.9	9
103	Application of 3D NMR for Structure Determination of Peptide Natural Products. <i>Journal of Organic Chemistry</i> , 2015 , 80, 8713-9	4.2	11
102	International expert opinion on the management of infection caused by azole-resistant <i>Aspergillus fumigatus</i> . <i>Drug Resistance Updates</i> , 2015 , 21-22, 30-40	23.2	210
101	Host contributions to construction of three device-associated <i>Candida albicans</i> biofilms. <i>Infection and Immunity</i> , 2015 , 83, 4630-8	3.7	45
100	Development of New Strategies for Echinocandins: Progress in Translational Research. <i>Clinical Infectious Diseases</i> , 2015 , 61 Suppl 6, S601-3	11.6	6
99	Fungal Biofilms: In Vivo Models for Discovery of Anti-Biofilm Drugs. <i>Microbiology Spectrum</i> , 2015 , 3,	8.9	45
98	Fungal Biofilms: In Vivo Models for Discovery of Anti-Biofilm Drugs 2015 , 33-49		2
97	Histoplasmosis complicating tumor necrosis factor- α blocker therapy: a retrospective analysis of 98 cases. <i>Clinical Infectious Diseases</i> , 2015 , 61, 409-17	11.6	85
96	Nontoxic antimicrobials that evade drug resistance. <i>Nature Chemical Biology</i> , 2015 , 11, 481-7	11.7	54
95	An expanded regulatory network temporally controls <i>Candida albicans</i> biofilm formation. <i>Molecular Microbiology</i> , 2015 , 96, 1226-39	4.1	104
94	Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 1265-72	5.9	73
93	Antifungal pharmacokinetics and pharmacodynamics. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2014 , 5, a019653	5.4	58
92	Searching for new derivatives of neocryptolepine: synthesis, antiproliferative, antimicrobial and antifungal activities. <i>European Journal of Medicinal Chemistry</i> , 2014 , 78, 304-13	6.8	20
91	Forazoline A: marine-derived polyketide with antifungal in vivo efficacy. <i>Angewandte Chemie - International Edition</i> , 2014 , 53, 11583-6	16.4	70
90	Rat indwelling urinary catheter model of <i>Candida albicans</i> biofilm infection. <i>Infection and Immunity</i> , 2014 , 82, 4931-40	3.7	31

89	Pharmacodynamics of Quinolone Antimicrobial Agents 2014 , 147-155		1
88	Comparative phenotypic analysis of the major fungal pathogens <i>Candida parapsilosis</i> and <i>Candida albicans</i> . <i>PLoS Pathogens</i> , 2014 , 10, e1004365	7.6	80
87	A histone deacetylase complex mediates biofilm dispersal and drug resistance in <i>Candida albicans</i> . <i>MBio</i> , 2014 , 5, e01201-14	7.8	50
86	Novel entries in a fungal biofilm matrix encyclopedia. <i>MBio</i> , 2014 , 5, e01333-14	7.8	194
85	Fungal biofilms, drug resistance, and recurrent infection. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2014 , 4,	5.4	146
84	Epidemiology and outcomes of invasive candidiasis due to non- <i>albicans</i> species of <i>Candida</i> in 2,496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004-2008. <i>PLoS ONE</i> , 2014 , 9, e101510	3.7	257
83	The Role of Biofilm Matrix in Mediating Antifungal Resistance 2014 , 1-14		
82	Race and invasive fungal infection in solid organ transplant recipients. <i>Ethnicity and Disease</i> , 2014 , 24, 382-5	1.8	2
81	Mechanisms of <i>Candida</i> biofilm drug resistance. <i>Future Microbiology</i> , 2013 , 8, 1325-37	2.9	233
80	Antifungal therapy: current concepts and evidence-based management. <i>Current Medical Research and Opinion</i> , 2013 , 29, 289-290	2.5	0
79	Posaconazole pharmacodynamic target determination against wild-type and Cyp51 mutant isolates of <i>Aspergillus fumigatus</i> in an in vivo model of invasive pulmonary aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 579-85	5.9	55
78	Insights into fungal pathogenesis from the iatrogenic epidemic of <i>Exserohilum rostratum</i> fungal meningitis. <i>Fungal Genetics and Biology</i> , 2013 , 61, 143-5	3.9	14
77	Optimizing antifungal choice and administration. <i>Current Medical Research and Opinion</i> , 2013 , 29 Suppl 4, 13-8	2.5	71
76	Regulatory role of glycerol in <i>Candida albicans</i> biofilm formation. <i>MBio</i> , 2013 , 4, e00637-12	7.8	55
75	Isavuconazole pharmacodynamic target determination for <i>Candida</i> species in an in vivo murine disseminated candidiasis model. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 5642-8	5.9	47
74	Inoculum effects of ceftobiprole, daptomycin, linezolid, and vancomycin with <i>Staphylococcus aureus</i> and <i>Streptococcus pneumoniae</i> at inocula of 10(5) and 10(7) CFU injected into opposite thighs of neutropenic mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 1434-41	5.9	41
73	Impact of in vivo triazole and echinocandin combination therapy for invasive pulmonary aspergillosis: enhanced efficacy against Cyp51 mutant isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 5438-47	5.9	26
72	Reply to Oude Lashof and Vogelaers. <i>Clinical Infectious Diseases</i> , 2013 , 56, 1515-6	11.6	1

71	Isavuconazole (BAL4815) pharmacodynamic target determination in an in vivo murine model of invasive pulmonary aspergillosis against wild-type and cyp51 mutant isolates of <i>Aspergillus fumigatus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 6284-9	5.9	67
70	Clinical pharmacodynamic index identification for micafungin in esophageal candidiasis: dosing strategy optimization. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 5714-6	5.9	26
69	Preparation of Biofilms for Transmission Electron Microscopy. <i>Bio-protocol</i> , 2013 , 3,	0.9	1
68	Preparation of <i>Candida albicans</i> Biofilms Using an in vivo Rat Central Venous Catheter Model. <i>Bio-protocol</i> , 2013 , 3,	0.9	3
67	Loss of CclA, required for histone 3 lysine 4 methylation, decreases growth but increases secondary metabolite production in <i>Aspergillus fumigatus</i> . <i>PeerJ</i> , 2013 , 1, e4	3.1	50
66	Comparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine <i>Staphylococcus aureus</i> pneumonia model. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 5916-22	5.9	44
65	A recently evolved transcriptional network controls biofilm development in <i>Candida albicans</i> . <i>Cell</i> , 2012 , 148, 126-38	56.2	473
64	Comparative analysis of <i>Candida</i> biofilm quantitation assays. <i>Medical Mycology</i> , 2012 , 50, 214-8	3.9	64
63	Modeling of fungal biofilms using a rat central vein catheter. <i>Methods in Molecular Biology</i> , 2012 , 845, 547-56	1.4	13
62	A <i>Candida</i> biofilm-induced pathway for matrix glucan delivery: implications for drug resistance. <i>PLoS Pathogens</i> , 2012 , 8, e1002848	7.6	190
61	Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. <i>Clinical Infectious Diseases</i> , 2012 , 54, 1110-22	11.6	545
60	Optimizing Echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against <i>Candida glabrata</i> with and without fks mutations. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 5875-82	5.9	36
59	Optimizing a <i>Candida</i> biofilm microtiter plate model for measurement of antifungal susceptibility by tetrazolium salt assay. <i>Journal of Clinical Microbiology</i> , 2011 , 49, 1426-33	9.7	106
58	Conserved and divergent roles of Bcr1 and CFEM proteins in <i>Candida parapsilosis</i> and <i>Candida albicans</i> . <i>PLoS ONE</i> , 2011 , 6, e28151	3.7	64
57	Interface of <i>Candida albicans</i> biofilm matrix-associated drug resistance and cell wall integrity regulation. <i>Eukaryotic Cell</i> , 2011 , 10, 1660-9		116
56	Protein binding: do we ever learn?. <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 3067-74	5.9	181
55	Fungal sepsis: optimizing antifungal therapy in the critical care setting. <i>Critical Care Clinics</i> , 2011 , 27, 123-47	4.5	37
54	Antifungal PK/PD considerations in fungal pulmonary infections. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2011 , 32, 783-94	3.9	13

53	Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia. <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 2113-21	5.9	84
52	Antifungal Pharmacokinetics and Pharmacodynamics 2011 , 121-134		3
51	Hsp90 governs dispersion and drug resistance of fungal biofilms. <i>PLoS Pathogens</i> , 2011 , 7, e1002257	7.6	196
50	Calcineurin controls drug tolerance, hyphal growth, and virulence in <i>Candida dubliniensis</i> . <i>Eukaryotic Cell</i> , 2011 , 10, 803-19		81
49	Comparison of in vitro susceptibility characteristics of <i>Candida</i> species from cases of invasive candidiasis in solid organ and stem cell transplant recipients: Transplant-Associated Infections Surveillance Network (TRANSNET), 2001 to 2006. <i>Journal of Clinical Microbiology</i> , 2011 , 49, 2404-10	9.7	37
48	Azoles 2011 , 61-93		1
47	Role of Fks1p and matrix glucan in <i>Candida albicans</i> biofilm resistance to an echinocandin, pyrimidine, and polyene. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 3505-8	5.9	155
46	Factors associated with mortality in transplant patients with invasive aspergillosis. <i>Clinical Infectious Diseases</i> , 2010 , 50, 1559-67	11.6	223
45	Genetic basis of <i>Candida</i> biofilm resistance due to drug-sequestering matrix glucan. <i>Journal of Infectious Diseases</i> , 2010 , 202, 171-5	7	193
44	Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. <i>Clinical Infectious Diseases</i> , 2010 , 50, 1091-100	11.6	991
43	Development and validation of an in vivo <i>Candida albicans</i> biofilm denture model. <i>Infection and Immunity</i> , 2010 , 78, 3650-9	3.7	120
42	Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). <i>Clinical Infectious Diseases</i> , 2010 , 50, 1101-11	11.6	1048
41	The role of second-generation antifungal triazoles for treatment of the endemic mycoses. <i>Current Infectious Disease Reports</i> , 2010 , 12, 471-8	3.9	6
40	Biofilm matrix regulation by <i>Candida albicans</i> Zap1. <i>PLoS Biology</i> , 2009 , 7, e1000133	9.7	233
39	Antifungal therapeutic drug monitoring: established and emerging indications. <i>Antimicrobial Agents and Chemotherapy</i> , 2009 , 53, 24-34	5.9	386
38	Voriconazole use for endemic fungal infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2009 , 53, 1648-51	5.9	107
37	Time course global gene expression analysis of an in vivo <i>Candida</i> biofilm. <i>Journal of Infectious Diseases</i> , 2009 , 200, 307-13	7	131
36	Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2009 , 48, 503-35	11.6	2247

35	Complementary adhesin function in <i>C. albicans</i> biofilm formation. <i>Current Biology</i> , 2008 , 18, 1017-24	6.3	247
34	Synergistic effect of calcineurin inhibitors and fluconazole against <i>Candida albicans</i> biofilms. <i>Antimicrobial Agents and Chemotherapy</i> , 2008 , 52, 1127-32	5.9	177
33	Association of fluconazole pharmacodynamics with mortality in patients with candidemia. <i>Antimicrobial Agents and Chemotherapy</i> , 2008 , 52, 3022-8	5.9	124
32	Activities of clindamycin, daptomycin, doxycycline, linezolid, trimethoprim-sulfamethoxazole, and vancomycin against community-associated methicillin-resistant <i>Staphylococcus aureus</i> with inducible clindamycin resistance in murine thigh infection and in vitro pharmacodynamic models. <i>Antimicrobial Agents and Chemotherapy</i> , 2008 , 52, 2156-62	5.9	77
31	Reduced biocide susceptibility in <i>Candida albicans</i> biofilms. <i>Antimicrobial Agents and Chemotherapy</i> , 2008 , 52, 3411-3	5.9	53
30	Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. <i>Therapeutic Drug Monitoring</i> , 2008 , 30, 167-72	3.2	124
29	Pharmacodynamics of antifungal drugs: A strategy to optimize efficacy. <i>Current Fungal Infection Reports</i> , 2008 , 2, 12-19	1.4	1
28	Review of techniques for diagnosis of catheter-related <i>Candida</i> biofilm infections. <i>Current Fungal Infection Reports</i> , 2008 , 2, 237-243	1.4	4
27	Putative role of beta-1,3 glucans in <i>Candida albicans</i> biofilm resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2007 , 51, 510-20	5.9	306
26	In vivo pharmacodynamic activity of the glycopeptide dalbavancin. <i>Antimicrobial Agents and Chemotherapy</i> , 2007 , 51, 1633-42	5.9	85
25	CNS pharmacokinetics of antifungal agents. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2007 , 3, 573-581	5.5	87
24	Beta -1,3 glucan as a test for central venous catheter biofilm infection. <i>Journal of Infectious Diseases</i> , 2007 , 195, 1705-12	7	76
23	Pharmacokinetics and Pharmacodynamics of Tetracyclines. <i>Infectious Disease and Therapy</i> , 2007 , 267-278		16
22	Antifungal Agents Pharmacokinetics and Pharmacodynamics of Amphotericin B. <i>Infectious Disease and Therapy</i> , 2007 , 315-326		
21	Critical role of Bcr1-dependent adhesins in <i>C. albicans</i> biofilm formation in vitro and in vivo. <i>PLoS Pathogens</i> , 2006 , 2, e63	7.6	387
20	Regulation of Iron Transport in <i>Streptococcus pneumoniae</i> by RitR, an Orphan Response Regulator. <i>Journal of Bacteriology</i> , 2006 , 188, 6045-6045	3.5	78
19	Pharmacology of Systemic Antifungal Agents. <i>Clinical Infectious Diseases</i> , 2006 , 43, S28-S39	11.6	211
18	Pharmacokinetics and pharmacodynamics of antifungals. <i>Infectious Disease Clinics of North America</i> , 2006 , 20, 679-97	6.5	83

17	Candida albicans biofilm development, modeling a host-pathogen interaction. <i>Current Opinion in Microbiology</i> , 2006 , 9, 340-5	7.9	162
16	Polymeric Micelles for the Delivery of Polyene Antibiotics. <i>ACS Symposium Series</i> , 2006 , 14-26	0.4	1
15	Imaging of the Development and Therapeutic Response of an In Vivo Fungal Catheter Biofilm. <i>Microscopy Today</i> , 2005 , 13, 30-33	0.4	
14	Use of an animal model of disseminated candidiasis in the evaluation of antifungal therapy. <i>Methods in Molecular Medicine</i> , 2005 , 118, 111-28		19
13	The Microbe-Host Interface in Respiratory Tract Infections Edited by Jan L. L. Kimpen and Octavio Ramilo Wymondham, UK: Horizon Bioscience, 2005. 323 pp., illustrated. \$139.95 (cloth). <i>Clinical Infectious Diseases</i> , 2005 , 41, 767-768	11.6	
12	In vivo pharmacodynamic activity of daptomycin. <i>Antimicrobial Agents and Chemotherapy</i> , 2004 , 48, 63-8	5.9	287
11	Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections. <i>Clinics in Laboratory Medicine</i> , 2004 , 24, 477-502	2.1	68
10	Antifungal pharmacokinetics and pharmacodynamics: understanding the implications for antifungal drug resistance. <i>Drug Resistance Updates</i> , 2004 , 7, 185-94	23.2	13
9	Clinical utility of antifungal pharmacokinetics and pharmacodynamics. <i>Current Opinion in Infectious Diseases</i> , 2004 , 17, 533-40	5.4	36
8	Clinical pharmacodynamics of antifungals. <i>Infectious Disease Clinics of North America</i> , 2003 , 17, 635-49	6.5	22
7	In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis. <i>Antimicrobial Agents and Chemotherapy</i> , 2003 , 47, 1179-86	5.9	139
6	Treatment of Community-Acquired Respiratory Tract Infections with Other Antibiotics 2003 , 145-153		
5	Pharmacokinetics and pharmacodynamics in the development of antifungal compounds. <i>Current Opinion in Investigational Drugs</i> , 2003 , 4, 991-8		9
4	Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo. <i>Antimicrobial Agents and Chemotherapy</i> , 1999 , 43, 2473-8	5.9	61
3	Pharmacodynamics of fluoroquinolones in experimental models of endocarditis. <i>Clinical Infectious Diseases</i> , 1998 , 27, 47-50	11.6	55
2	Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. <i>Pediatric Infectious Disease Journal</i> , 1996 , 15, 255-9	3.4	360
1	Antifungals: Drug Class, Mechanisms of Action, Pharmacokinetics/Pharmacodynamics, Drug-Drug Interactions, Toxicity, and Clinical Use 343-371		3